arrow_back Back to App

Drug Shortage Prevention: Early Warning for Increased Demand of Critical Medicines.

This Act aims to protect citizens from sudden shortages of life-saving or essential medicines for serious conditions. It mandates manufacturers to notify authorities not only of production interruptions but also of significant increases in demand for critical drugs. This allows the government and healthcare providers to react faster, minimizing the risk of patients being deprived of necessary treatments.
Key points
Mandatory Reporting of Increased Demand: Manufacturers must inform authorities about increased demand for critical essential medicines if it lasts for at least 6 consecutive weeks and is likely to lead to a shortage.
Early Warning System: Notification of production discontinuation or increased demand must be submitted in advance (6 months or within 48 hours of identifying the demand surge), allowing time to secure alternative supplies.
Definition of Critical Medicines: The Act defines critical essential medicines as those that are life-supporting, life-sustaining, or intended for debilitating diseases, including nonprescription drugs.
Increased Transparency: Manufacturers must provide reasons for interruptions or demand increases, including information on the source of active ingredients and any alternative sources.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_3008
Sponsor: Rep. Jacobs, Sara [D-CA-51]
Process start date: 2023-04-28
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Drug Shortage Prevention Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_3008.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-04-28.

What are the main provisions?

Key points include:

  • Mandatory Reporting of Increased Demand: Manufacturers must inform authorities about increased demand for critical essential medicines if it lasts for at least 6 consecutive weeks and is likely to lead to a shortage.
  • Early Warning System: Notification of production discontinuation or increased demand must be submitted in advance (6 months or within 48 hours of identifying the demand surge), allowing time to secure alternative supplies.
  • Definition of Critical Medicines: The Act defines critical essential medicines as those that are life-supporting, life-sustaining, or intended for debilitating diseases, including nonprescription drugs.
  • Increased Transparency: Manufacturers must provide reasons for interruptions or demand increases, including information on the source of active ingredients and any alternative sources.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Jacobs, Sara [D-CA-51].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-30.

CATEGORIES

Health